IDEAS home Printed from https://ideas.repec.org/p/ehl/lserod/326.html
   My bibliography  Save this paper

Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy

Author

Listed:
  • McCrone, Paul R.
  • Chisholm, Daniel
  • Knapp, Martin
  • Hughes, Richard
  • Comi, Giancarlo
  • Dalakas, Marinos C.
  • Illa, Isabel
  • Kilindireas, Costas
  • Nobile-Orazio, Eduardo
  • Swan, Anthony Victor
  • Van den Bergh, Peter
  • Willison, Hugh J.

Abstract

There is a paucity of economic evidence relating to interventions for peripheral nerve disorders and the aim of this study was to illustrate the application of economic evaluation in this area by making a comparison of the cost-effectiveness of intravenous immunoglobulin and prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Patients (n=32) were recruited to a double-blind randomised cross-over trial from nine European centres and received either prednisolone or intravenous immunoglobulin during the first six-week treatment period, followed by a four-week washout period after which the other treatment was received. Service use, quality of life and physical disability were measured at baseline and at the end of both treatment periods. Cost and outcome data were available for 25 patients who completed the first arm of the study but for only 16 who completed both arms. Therefore, the focus of the economic evaluation was on the initial treatment period. Baseline costs were controlled for using a bootstrapped multiple regression model. The cost difference between the two treatments was estimated to be £1608 for the initial six week period. Physical disability fell over six weeks in both groups without any significant difference between them. Health-related quality of life, as measured by the EQ-5D, increased more in the IVIg group and this difference approached statistical significance. The incremental cost per QALY of IVIg compared to prednisolone was estimated to be £107,200. The cost per QALY is greatly affected by the price of IVIg and the amount administered. The impact of side effects on long-term costs and quality of life are likely to reduce the cost per QALY of IVIg treatment compared to prednisolone.

Suggested Citation

  • McCrone, Paul R. & Chisholm, Daniel & Knapp, Martin & Hughes, Richard & Comi, Giancarlo & Dalakas, Marinos C. & Illa, Isabel & Kilindireas, Costas & Nobile-Orazio, Eduardo & Swan, Anthony Victor & Van, 2003. "Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy," LSE Research Online Documents on Economics 326, London School of Economics and Political Science, LSE Library.
  • Handle: RePEc:ehl:lserod:326
    as

    Download full text from publisher

    File URL: http://eprints.lse.ac.uk/326/
    File Function: Open access version.
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Alan Williams, 1995. "The role of the Euroqol instrument in QALY calculations," Working Papers 130chedp, Centre for Health Economics, University of York.
    2. Kevin Schulman & Jennifer Burke & Michael Drummond & Linda Davies & Per Carlsson & Jans Gruger & Anthony Harris & Carlo Lucioni & Ramon Gisbert & Ted Llana & Eric Tom & Bernard Bloom & Richard Willke , 1998. "Resource costing for multinational neurologic clinical trials: methods and results," Health Economics, John Wiley & Sons, Ltd., vol. 7(7), pages 629-638, November.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Paul Cross & Rhiannon T Edwards & Philip Nyeko & Gareth Edwards-Jones, 2009. "The Potential Impact on Farmer Health of Enhanced Export Horticultural Trade between the U.K. and Uganda," IJERPH, MDPI, vol. 6(5), pages 1-18, April.
    2. Richard Grieve & John Cairns & Simon G. Thompson, 2010. "Improving costing methods in multicentre economic evaluation: the use of multiple imputation for unit costs," Health Economics, John Wiley & Sons, Ltd., vol. 19(8), pages 939-954, August.
    3. José Ferraz-Nunes, 2005. "Cost-Effective Prevention of Hip Fractures," International Advances in Economic Research, Springer;International Atlantic Economic Society, vol. 11(1), pages 49-67, February.
    4. I. Mosweu & R. Moss-Morris & L. Dennison & T. Chalder & P. McCrone, 2017. "Cost-effectiveness of nurse-delivered cognitive behavioural therapy (CBT) compared to supportive listening (SL) for adjustment to multiple sclerosis," Health Economics Review, Springer, vol. 7(1), pages 1-9, December.
    5. Andrew R. Willan & Eleanor M. Pinto & Bernie J. O'Brien & Padma Kaul & Ron Goeree & Larry Lynd & Paul W. Armstrong, 2005. "Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT‐3 economic analysis," Health Economics, John Wiley & Sons, Ltd., vol. 14(4), pages 327-338, April.
    6. Sarah Wordsworth & Anne Ludbrook, 2005. "Comparing costing results in across country economic evaluations: the use of technology specific purchasing power parities," Health Economics, John Wiley & Sons, Ltd., vol. 14(1), pages 93-99, January.
    7. Mengjun Wu & John Brazier & Benjamin Kearns & Clare Relton & Christine Smith & Cindy Cooper, 2015. "Examining the impact of 11 long-standing health conditions on health-related quality of life using the EQ-5D in a general population sample," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(2), pages 141-151, March.
    8. Juan Manuel Cabasés & Idoia Gaminde & José M. Ugalde, 2000. "Societal perspective on the eliciting of health states preferences," Documentos de Trabajo - Lan Gaiak Departamento de Economía - Universidad Pública de Navarra 0010, Departamento de Economía - Universidad Pública de Navarra.
    9. Christopher J.L. Murray & David B. Evans & Arnab Acharya & Rob M.P.M. Baltussen, 2000. "Development of WHO guidelines on generalized cost‐effectiveness analysis," Health Economics, John Wiley & Sons, Ltd., vol. 9(3), pages 235-251, April.
    10. Raymond Oppong & Joanna Coast & Kerry Hood & Jacqui Nuttall & Richard Smith & Christopher Butler, 2011. "Resource use and costs of treating acute cough/lower respiratory tract infections in 13 European countries: results and challenges," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(4), pages 319-329, August.
    11. Jonas Schreyögg & Oliver Tiemann & Tom Stargardt & Reinhard Busse, 2008. "Cross‐country comparisons of costs: the use of episode‐specific transitive purchasing power parities with standardised cost categories," Health Economics, John Wiley & Sons, Ltd., vol. 17(S1), pages 95-103, January.
    12. Melissa Lannon & Taylor Duda & Alexander Mastrolonardo & Ellissa Huang & Amanda Martyniuk & Forough Farrokhyar & Feng Xie & Mohit Bhandari & Suneil K. Kalia & Sunjay Sharma, 2024. "Economic Evaluations Comparing Deep Brain Stimulation to Best Medical Therapy for Movement Disorders: A Meta-Analysis," PharmacoEconomics, Springer, vol. 42(1), pages 41-68, January.
    13. Richard Grieve & Richard Nixon & Simon G. Thompson, 2010. "Bayesian Hierarchical Models for Cost-Effectiveness Analyses that Use Data from Cluster Randomized Trials," Medical Decision Making, , vol. 30(2), pages 163-175, March.
    14. Sarah Wordsworth & Anne Ludbrook & Fergus Caskey & Alison Macleod, 2005. "Collecting unit cost data in multicentre studies," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(1), pages 38-44, March.
    15. Raymond Oppong & Sue Jowett & Tracy E Roberts, 2015. "Economic Evaluation alongside Multinational Studies: A Systematic Review of Empirical Studies," PLOS ONE, Public Library of Science, vol. 10(6), pages 1-22, June.
    16. Tarricone, Rosanna, 2006. "Cost-of-illness analysis: What room in health economics?," Health Policy, Elsevier, vol. 77(1), pages 51-63, June.
    17. repec:kap:iaecre:v:11:y:2005:i:1:p:49-67 is not listed on IDEAS
    18. Burstrom, Kristina & Johannesson, Magnus & Diderichsen, Finn, 2001. "Health-related quality of life by disease and socio-economic group in the general population in Sweden," Health Policy, Elsevier, vol. 55(1), pages 51-69, January.
    19. Zsombor Zrubka & Márta Péntek & Lea Mhanna & Teebah Abu-Zahra & Mohamed Mahdi-Abid & Meriem Fgaier & Faris El-Dahiyat & Hana Al-Abdulkarim & Michael Drummond & László Gulácsi, 2022. "Disease-Related Costs Published in The Middle East and North Africa Region: Systematic Review and Analysis of Transferability," PharmacoEconomics, Springer, vol. 40(6), pages 587-599, June.
    20. John Brazier & Mark Deverill, 1999. "A checklist for judging preference‐based measures of health related quality of life: Learning from psychometrics," Health Economics, John Wiley & Sons, Ltd., vol. 8(1), pages 41-51, February.

    More about this item

    Keywords

    chronic inflammatory demyelinating polyradiculoneuropathy; intravenous immunoglobulin; prednisolone; health care costs; quality-adjusted life years;
    All these keywords.

    JEL classification:

    • E6 - Macroeconomics and Monetary Economics - - Macroeconomic Policy, Macroeconomic Aspects of Public Finance, and General Outlook

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:ehl:lserod:326. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: LSERO Manager (email available below). General contact details of provider: https://edirc.repec.org/data/lsepsuk.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.